ASSESSING THE ACCURACY OF FIB-4 SCORES TO POINT SHEAR WAVE ELASTOGRAPHY IN MONITORING DIFFERENT STAGES OF FIBROSIS IN NON-ALCOHOLIC LIVER DISEASE

Authors

  • Shahla Mohammed Saeed Rasul Department of Surgery, College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.

DOI:

https://doi.org/10.17656/jsmc.10420

Keywords:

Fibrosis, 2-D SWE, liver cirrhosis, (NAFLD), serum markers, elastography, (FIB-4) scoring, point shear wave elastography, (APRI)

Abstract

Background
Non-alcoholic liver disease (NAFLD) assessment is done by measuring biochemical parameters from blood samples. However, non-invasive methods have gained significance lately. Biochemical parameters and staging of fibrosis-associated NAFLD based on the levels of biomarkers have been established procedures in the field. So, the utilization of non-invasive methods as a comparable means for fibrosis staging in NAFLD has yet to be established.


Objectives
To compare the diagnostic performance of serum markers to point shear wave elastography for classifying fibrosis in NAFLD and its staging.


Materials and Methods
Data were collected by laboratory tests and point shear wave elastography. A comparison of FIB-4 indexes scores and point shear wave elastography for the staging of fibrosis in NAFLD was made based on cross-tabulation of the quantitative data obtained.


Results
A positive and significant correlation between FIB4 and age, ALT, AST, RBS, AST/ ALT, AST/ UL AST, APRI, AST/ Platelet count, and point shear wave elastography (PSWE). The correlation was negative and non-significant between FIB4 and Weight, Height, BMI, UL AST, TSB, and Platelet count.


Conclusion
The study observed a positive correlation between FIB-4 and PSWE. Thus, the present study proposes the use of PSWE as a non-invasive diagnostic tool in the staging of fibrosis in NAFLD for patients with an intermediate FIB-4 score.

References

Piccinin E, Villani G, Moschetta A. Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators. Nature reviews Gastroenterology & hepatology. 2019;16(3):160-74. DOI: https://doi.org/10.1038/s41575-018-0089-3

Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH—current progress and future promise. Nature reviews Gastroenterology & hepatology. 2018;15(8):461-78. DOI: https://doi.org/10.1038/s41575-018-0014-9

Febbraio MA, Reibe S, Shalapour S, Ooi GJ, Watt MJ, Karin M. Preclinical models for studying Nash-driven hcc: How useful are they? Cell Metab. 2019: 29:18–26. doi: 10.1016/j.cmet.2018.10.012 DOI: https://doi.org/10.1016/j.cmet.2018.10.012

Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. Journal of Hepatology. 2018 ;68(2):268-79. DOI: https://doi.org/10.1016/j.jhep.2017.09.003

Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nature reviews Gastroenterology & hepatology. 2016;13(4):196-205.9. DOI: https://doi.org/10.1038/nrgastro.2016.3

Seghieri M, Christensen AS, Andersen A, Solini A, Knop FK, Vilsboll T. Future perspectives on glp-1 receptor agonists and glp-1/glucagon receptor co-agonists in the treatment of NAFLD. Front Endocrinol (Lausanne). 2018; 9:649. doi: 10.3389/fendo.2018.00649 DOI: https://doi.org/10.3389/fendo.2018.00649

Liu P, Feng T, Zuo X, Wang X, Luo J, Li N, et al. A novel sirt1 activator e6155 improves insulin sensitivity in type 2 diabetic kkay mice. Biochem Biophys Res Commun. 2018; 498:633–39. doi: 10.1016/j.bbrc.2018.03.034 DOI: https://doi.org/10.1016/j.bbrc.2018.03.034

Castera, Laurent, Mireen Friedrich-Rust, and Rohit Loomba. "Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease." Gastroenterology. 2019; 156(5):1264-1281. DOI: https://doi.org/10.1053/j.gastro.2018.12.036

Sun, Wenjing, Hongli Cui, Ning Li, Yanling Wei, Shujie Lai, Yang Yang, Xinru Yin, and Dong-Feng Chen. "Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study." Hepatology Research. 2016; 46(9):862-870. DOI: https://doi.org/10.1111/hepr.12647

Petroff, David, Olaf Bätz, Katrin Jedrysiak, Jan Kramer, Thomas Berg, and Johannes Wiegand. "Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples." Gut. 2021; 70(1): 219-221. DOI: https://doi.org/10.1136/gutjnl-2020-320995

Jiang W, Huang S, Teng H, et al. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis BMJ Open 2018;8:e021787 DOI: https://doi.org/10.1136/bmjopen-2018-021787

Liaqat M., Siddique K., Yousaf I., Bacha R., Farooq S., Gilani S.. Comparison between shear wave elastography and serological findings for the evaluation of fibrosis in chronic liver disease. Journal of Ultrasonography. 2021;21(86): 186-193. DOI: https://doi.org/10.15557/JoU.2021.0030

Published

2023-09-21

How to Cite

1.
Rasul S. ASSESSING THE ACCURACY OF FIB-4 SCORES TO POINT SHEAR WAVE ELASTOGRAPHY IN MONITORING DIFFERENT STAGES OF FIBROSIS IN NON-ALCOHOLIC LIVER DISEASE. JSMC [Internet]. 2023 Sep. 21 [cited 2024 Jul. 22];13(3):5. Available from: https://jsmc.univsul.edu.iq/index.php/jsmc/article/view/jsmc-10420

Similar Articles

1-10 of 120

You may also start an advanced similarity search for this article.